RT Journal Article
SR Electronic
T1 Adherence to Pre-exposure Prophylaxis intervention by transgender women: A systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.20.22283755
DO 10.1101/2022.12.20.22283755
A1 Moncayo-Quevedo, Jorge Eduardo
A1 Mar Pérez-Arizabaleta, María Del
A1 María Villegas-Trujillo, Lina
A1 Rodríguez-Ortiz, Alejandra
YR 2022
UL http://medrxiv.org/content/early/2022/12/21/2022.12.20.22283755.abstract
AB Background The prevalence of HIV is higher in the transgender population. Recently, the preexposure prophylaxis (PrEP) intervention has been proven successful in reducing HIV acquisition in trials among men who have sex with men (MSM), and heterosexual couples. This research aims to investigate the adherence to PrEP by HIV-negative transgender women (TW).Methods Were followed the Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA Statement. Research in WoS, Ovid, Scopus, MEDLINE, and the Cochrane Central Register of Controlled Trials (CENTRAL) electronic databases for studies that involved HIV-negative TW population and focused on their adherence to PrEP intervention and condom use after the treatment.Results 11 studies were included. TW sample sizes were low in comparison to the total sample, which often included men who have sex with men (MSM) population. The participation and adherence to the intervention was low compared to MSM, and it was measured mainly by self-report (72.7%) or by Tenofovir-diphosphate (TFV-DP)/ Emtricitabine triphosphate (FTC-TP) dried blood spot (DBS) (45.5%).Conclusions It is important to increase awareness and explain the effect of PrEP on feminizing hormone therapy at the beginning of the trials. Nevertheless, the low adherence may be affected by the interaction between drugs and the barriers faced to use the health services.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Ministry of Science Technology and Innovation of Colombia under Grant Number 123380763100Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.CENTRALCochrane Central Register of Controlled TrialsCIConfidence IntervalDBSDried Blood SpotFTC-TPEmtricitabine triphosphateHIVHuman Immunodeficiency VirusMSMMen who have Sex with MenOROdds RatioPrEPPreexposure ProphylaxisRRRisk RatioTFV-DPTenofovir-diphosphate